Published in Acta Oncol on April 18, 2013
Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep (2017) 1.38
Toward a Cancer Drug of Fungal Origin. Med Res Rev (2015) 0.81
Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis. Onco Targets Ther (2015) 0.75
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network. Cancer Chemother Pharmacol (2016) 0.75
Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? Oncotarget (2016) 0.75
Prediction of liver injury using the BP-ANN model with metabolic parameters in overweight and obese Chinese subjects. Int J Clin Exp Med (2015) 0.75
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer (2017) 0.75
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA (2011) 7.61
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA (2008) 7.13
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA (2011) 6.14
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol (2009) 2.87
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med (2011) 2.34
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res (2011) 2.27
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol (2006) 2.23
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol (2009) 2.23
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist (2008) 2.22
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol (2010) 2.18
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int (2011) 2.07
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol (2011) 2.02
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol (2012) 2.00
The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity (2005) 1.88
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. Eur Urol (2012) 1.86
Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer (2011) 1.85
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. Urology (2010) 1.83
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol (2009) 1.82
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. J Urol (2012) 1.78
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. J Clin Oncol (2014) 1.74
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007. BJU Int (2013) 1.73
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology (2010) 1.68
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. Haematologica (2006) 1.67
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer (2010) 1.52
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer (2010) 1.52
Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol (2010) 1.50
Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens (2010) 1.50
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol (2010) 1.48
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res (2006) 1.45
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol (2013) 1.45
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med (2014) 1.43
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer (2014) 1.41
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol (2008) 1.39
Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol (2010) 1.36
Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer (2009) 1.34
Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology (2010) 1.31
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol (2010) 1.29
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol (2012) 1.24
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clin Proc (2005) 1.22
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol (2010) 1.22
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol (2007) 1.13
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Patterns of care for radical prostatectomy in the United States from 2003 to 2005. J Urol (2008) 1.08
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer (2012) 1.07
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer (2012) 1.07
Kidney cancer. J Natl Compr Canc Netw (2011) 1.06
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension (2010) 1.05
Risk of bilateral renal cell cancer. J Clin Oncol (2009) 1.04
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep (2012) 1.03
Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma. Cancer J (2013) 1.00
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys (2011) 1.00
Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw (2009) 1.00
The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs (2011) 1.00
Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate (2011) 1.00
Treatment selection for patients with metastatic renal cell carcinoma. Cancer (2009) 0.99
Elicitation of health state utilities in metastatic renal cell carcinoma. Curr Med Res Opin (2010) 0.99
Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat Rev (2010) 0.98
Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer (2014) 0.98
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer (2008) 0.97
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist (2011) 0.97
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs (2013) 0.96
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab (2012) 0.96
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int (2007) 0.95
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med (2014) 0.95
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw (2011) 0.94
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med (2013) 0.94
Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology (2009) 0.94
Differential expression of caveolin-1 in renal neoplasms. Cancer (2007) 0.93
ABO blood group and risk of renal cell cancer. Cancer Epidemiol (2012) 0.93
Optimizing recent advances in metastatic renal cell carcinoma. Curr Oncol Rep (2009) 0.92
Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol (2011) 0.92
Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol (2008) 0.91